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Abstract
Background—The Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS) is a 
population-based, multi-Center case-control study of modifiable risk factors for selected birth 
defects in the United States. BD-STEPS is the second major research effort of the Centers for 
Birth Defects Research and Prevention, which extends and expands the initial research effort, the 
National Birth Defects Prevention Study (NBDPS).
Methods—BD-STEPS focuses on 17 categories of structural birth defects selected based on 
severity, prevalence, consistent ascertainment, and previous findings that warrant additional 
research. Cases are identified through existing birth defects surveillance programs; controls are 
from vital records or birth hospital logs from the same catchment area. BD-STEPS usess a 
standardized computer-assisted telephone interview to collect information from case and control 
mothers on topics including demographics, health conditions, and medication use. Following the 
maternal interview, selected Centers request permission to sample residual newborn screening 
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blood spots from state repositories for genetic analyses. New components planned for BD-STEPS 
include linkages with external datasets and use of online questionnaires to collect in-depth 
information on selected exposures.
Results—BD-STEPS extends NBDPS by continuing to collect data on many exposures that were 
assessed in NBDPS, allowing data from both studies to be combined and providing an 
unprecedented sample size to analyze rare exposures. BD-STEPS expands upon NBDPS by 
collecting more detailed information on existing exposures as well as new exposures.
Conclusions—The goal of BD-STEPS is to provide women and healthcare providers with 
information they need to make decisions to promote the healthiest pregnancy possible.
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INTRODUCTION
Birth defects are common, costly, and critical. Although some birth defects are caused by 
known genetic disorders (e.g., Trisomy 21) or environmental (i.e., non-genetic) exposures 
(e.g., thalidomide), the etiology is unknown for an estimated two-thirds of birth defects 
(Nelson and Holmes, 1989). Identifying modifiable risk factors for birth defects allows 
women, their partners, and health care providers to take preventive action.
The Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS) is a population-
based, multi-Center case-control study in the United States that focuses on understanding the 
role of modifiable risk factors for selected structural birth defects. BD-STEPS is a 
collaborative activity of the Centers for Birth Defects Research and Prevention (CBDRP), 
which were established in response to the Birth Defects Prevention Act of 1998. The first 
collaborative activity of the CBDRP was the National Birth Defects Prevention Study 
(NBDPS), a population-based, multi-Center case-control study of environmental and genetic 
risk factors for selected structural birth defects that interviewed nearly 44,000 women about 
their pregnancies in 10 CBDRP Centers across the United States (Yoon and others, 2001)
[add Reefhuis et al., this issue].
Over 200 NBDPS manuscripts were published between 2001 and 2014 on a wide range of 
topics [add Dawson et al., this issue]. Although the study sample size of NBDPS was 
unprecedented and allowed for examination of a wide variety of risk factors for birth 
defects, several research areas could benefit from additional study. BD-STEPS was designed 
to advance knowledge about specific modifiable risk factors for birth defects by extending 
and expanding the activities of NBDPS.
In September 2013, six CBDRP study Centers located in Arkansas (AR), California (CA), 
Iowa (IA), Massachusetts (MA), New York (NY), and North Carolina (NC), were funded to 
collaborate on BD-STEPS. As with NBDPS, the Centers for Disease Control and Prevention 
(CDC) contributes data from Georgia and serves as a seventh study Center. BD-STEPS 
benefits from a multidisciplinary team comprised of epidemiologists, biostatisticians, 
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clinicians (including clinical geneticists, pediatricians, pediatric cardiologists, and 
perinatologists), geneticists, study coordinators, data managers, and interviewers.
The purpose of this paper is to provide an overview of the BD-STEPS rationale and design.
METHODS OVERVIEW
Study design
BD-STEPS is a population-based, multi-Center case-control study. All English or Spanish 
speaking women who reside within defined ascertainment areas and experienced a 
pregnancy for which at least one eligible birth defect was reported in an active, population-
based birth defects surveillance system are recruited for inclusion in the study. All Centers 
include cases that are live births, fetal deaths (stillbirths), or pregnancies ending in 
terminations (to the extent possible). Population-based controls are live born infants without 
a diagnosis of any major birth defects and are identified through vital records (AR, IA, MA, 
GA, NC Centers) or hospital records (CA and NY Centers).
The birth population encompassed within each of the participating BD-STEPS Centers 
ranges from 35,000 to 70,000 (Table 1). We estimate that approximately 1,400 case 
pregnancies with eligible defects will be identified study-wide per year. Each Center will 
identify approximately 100 to 125 eligible control infants per year. Based on the experience 
of NBDPS, we estimate the participation rate will be close to 70%, resulting in completed 
interviews for approximately 1,000 cases and 500 controls per year. BD-STEPS data 
collection began with births on or after January 1, 2014.
The population-based, multi-Center design of BD-STEPS, combined with the geographic 
and racial/ethnic diversity of the BD-STEPS study population, is important for minimizing 
potential bias and improving generalizability of the results from this study to other 
populations. A comparison of the maternal demographic characteristics of NBDPS control 
mothers with those of all U.S. births supports the scientific merits of this approach with 
respect to the representativeness and generalizability of the study findings (Cogswell and 
others, 2009).
Critical partnerships with BD surveillance programs: The foundation for case-finding
BD-STEPS builds upon key partnerships between the CDC, academic institutions, and state 
health departments established for NBDPS. An essential component of these partnerships is 
the population-based birth defect surveillance programs within each of the study Centers. 
These surveillance programs provide the basis for clinical data collection at each of the 
seven Centers. Some BD-STEPS Centers are housed within or closely collaborate with the 
state health department that manages the birth defects surveillance program (MA, NY, NC), 
while other Centers are housed within a university or federal agency that has arrangements 
with the state health department to conduct birth defects surveillance activities (AR, CA, 
GA, IA). Each of the surveillance programs has statutory authority from their respective 
states to review and abstract maternal and infant medical records in order to collect birth 
defects data, and has authority to use that information for public health research with 
appropriate approvals. Local agreements within each participating Center provide for the use 
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of birth defect surveillance and vital records data to recruit study participants for BD-
STEPS. Use of existing population-based surveillance systems is an expedient and highly 
cost-effective approach for the conduct of large, multi-Center epidemiologic studies such as 
BD-STEPS.
Clinical methods
The clinical methods of BD-STEPS are similar to those of the NBDPS (Rasmussen and 
others, 2003), but with a more limited number of birth defects. Medical record data 
abstracted by the birth defects surveillance programs are searched using a list of eligible 
ICD-codes. Identified records are then reviewed by a clinical geneticist at each study Center 
to determine whether each case meets diagnostic criteria for inclusion. The primary 
inclusion criterion is the presence of at least one of the 17 categories of eligible structural 
defects (Table 2). These defects were chosen for BD-STEPS based on severity (i.e., 
associated with infant deaths, disabilities, comorbidities, or high healthcare costs), 
prevalence (i.e., retained more common NBDPS defects), or high public health importance 
(e.g., all seven types of critical congenital heart defects that are primary targets for newborn 
screening using pulse oximetry (Kemper and others, 2011)); consistent ascertainment 
(enabling more homogeneous and complete case groups); and results from previous findings 
that supported further research (e.g., NBDPS data helped document the existence of a new 
teratogen - mycophenolate mofetil – and its association with anotia/microtia (Anderka and 
others, 2009)). Defects that did not have these characteristics were not selected for this 
study. For example, anencephaly is lethal, relatively common, and has been the intense 
focus of previous public health research and prevention programs; however, ascertainment 
varied across NBDPS due to the relative infrequency of live births among pregnancies with 
anencephaly (Cragan and Gilboa, 2009) and varying sources of prenatal data with 
inconsistent ascertainment of terminated pregnancies. Therefore, anencephaly was not 
included as an eligible birth defect in BD-STEPS. The combined prevalence of the 17 birth 
defect categories included in BD-STEPS is estimated to be approximately 39.2 cases per 
10,000 live births.
Like NBDPS, BD-STEPS excludes infants with recognized or strongly-suspected 
chromosomal or single-gene disorders. Case definitions with defect-specific inclusion and 
exclusion criteria are used by clinicians at each study Center to determine eligibility of 
individual cases. Once data are compiled across Centers, each case is subjected to a second 
level of clinical review, in which a single clinician will review and classify all cases within a 
particular category of defects. This classification process includes a review for consistency 
of coding and inclusion among the various study Centers, as well as further categorization 
into homogeneous analysis groups based on the presence or absence of multiple major 
defects and defect patterns.
Recruitment
The recruitment process for BD-STEPS is similar to that of the NBDPS. Contact 
information is identified through the abstracted medical or vital record, and when necessary, 
a commercial tracing service is used. An introductory packet is mailed to prospective study 
participants by staff located at the individual study Centers no earlier than six weeks after 
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the estimated date of delivery (EDD). The introductory packet, with all documents in 
English and Spanish, includes a letter of introduction, a fact sheet on rights of human 
subjects, a question and answer sheet, a $20 gift card, and materials to assist with recall 
during the interview (a calendar covering the period of the pregnancy and a chart for 
summarizing medication information).
Interviewers begin placing calls 4 to 10 days after the introductory packets are mailed. An 
interview can be initiated up to 18 months after EDD. This eligibility period allows 
sufficient time for complete diagnosis of the defects and ascertainment by the birth defects 
surveillance programs. Trained study interviewers use approved standardized telephone 
scripts for all study communications. Comprehensive tracing methods are used to maximize 
participation rates and include several follow-up calls, letters, and emails to locate hard-to-
reach women.
Interview
The BD-STEPS maternal interviews are conducted in English and Spanish by a centralized 
interview contractor to maximize efficiency and standardization of data collection and 
provide bilingual interviewers during all call hours. For all Centers, maternal verbal 
informed consent is obtained at the beginning of the interview with the exception of two 
Centers. One Center’s state requires that informed consent be obtained locally for all births 
and another Center’s state requires local written consent for women whose pregnancy ended 
in an elective termination.
Interviewers are all female and receive intensive initial and on-going training on the use of 
the BD-STEPS computer-assisted telephone interview (CATI) instrument. Interviewers are 
monitored, initially on all interviews, and then randomly after they have gained experience. 
Women can complete interviews during the day or in the evening, and on weekdays or 
weekends at their convenience. The topics included in the BD-STEPS CATI are listed in 
Table 3.
The BD-STEPS interview was designed to be shorter in duration than the NBDPS interview, 
taking approximately 45 minutes to complete (versus approximately 60 minutes for 
NBDPS), to reduce subject burden and increase the likelihood of completing the interview 
in one session (although women have the option to complete the interview in multiple 
sessions). Several topic areas that were included in the NBDPS interview were removed, 
either because sufficient data were available from NBDPS (e.g., dietary data from a food 
frequency questionnaire) or future study was not deemed to have the same potential for 
additional discovery.
The BD-STEPS interview was also designed such that some data could be combined with 
data from NBDPS for increased power. For some rarer exposures (e.g., use of venlafaxine 
(Polen and others, 2013)), data can be combined to produce more stable estimates of 
association. Where possible, we maintained exact or similar wording for questions covering 
topics also included in the NBDPS interview (e.g., questions on race, education, 
acculturation, and some of the disease and medication questions). NBDPS questions about 
physical activity, stress, and social support were introduced later during the study and were 
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retained in BD-STEPS in order to accumulate data. In the BD-STEPS interview, we also 
chose to expand on topics that had a limited number of questions in the NBDPS interview. 
These topics include fertility treatments, details of multiple gestation (i.e., twins and higher 
order pregnancies), and chronic diseases and health conditions (e.g., obesity, thyroid disease, 
asthma, cancer, migraines, autoimmune disease, depression, anxiety, and attention deficit 
hyperactivity disorder [ADHD]). New topic areas in the BD-STEPS questionnaire include 
maternal dental procedures and insurance status.
The time period for which we ask women to report their exposures and experiences is 
shortened in BD-STEPS. Because structural birth defects primarily occur during the first 
trimester of pregnancy, most of the BD-STEPS questions focus on the one month before 
through the third month of pregnancy. Advantages of shortening the exposure period are that 
women have a shorter time period for which to recall and possibly fewer exposures to report 
due to the elimination of exposures that may have only occurred later in pregnancy. A 
limitation of the shortened exposure period is that we will not be able to describe exposure 
prevalence during the entire pregnancy; analyses of the prevalence of exposure patterns 
among our population-based controls will be able to focus on early pregnancy.
New and expanded focus areas
Chronic maternal medical conditions: One key topic area expanded in BD-STEPS is 
chronic maternal medical conditions, for which more detailed information is being collected 
about specific conditions during pregnancy, including when women were diagnosed, 
whether women spoke to their healthcare providers about management of their condition 
during pregnancy, the medications or other treatments used to treat her condition, and 
symptoms experienced during pregnancy. There are several reasons for this intensified focus 
on chronic maternal medical conditions. Certain serious conditions previously thought to 
preclude pregnancy are now more easily managed so that women of childbearing age have 
increased survival and opportunity for pregnancy. For example, cancer is diagnosed in 1 in 
every 1,000 pregnancies and 160,000 to 240,000 women of childbearing age (<45 years) 
received a cancer diagnosis in 2013 (Salani and others, 2014). As another example, 
transplant receipt typically requires lifetime immunosuppression maintenance and one well-
known antirejection medication, mycophenolate mofetil, has been recently identified as a 
human teratogen (Anderka and others, 2009).
Other chronic conditions show increasing prevalence over time among women of 
childbearing age, making it even more important that we understand the implications of 
diagnosis and management of these conditions during pregnancy. Asthma prevalence 
increased steadily over the previous decade and is common among women (9%) (Akinbami 
and others, 2012). NBDPS analyses showed a possible association between asthma 
medication use and increased risk for specific birth defects (Lin and others, 2008; Lin and 
others, 2012; Munsie and others, 2011); however, confounding by indication could not be 
ruled out in these analyses due to a lack of detailed information on asthma status and 
severity; BD-STEPS will collect this additional information. Depression has also shown an 
increasing prevalence over time, from 3% in 1991 (Compton and others, 2006) to 9% in 
2006 – 2008 (Centers for Disease and Prevention, 2010) and is common among women 
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(10%) (Centers for Disease and Prevention, 2010). Depression may influence risk for birth 
defects through stress or other physiological response; use of medications, which have 
previously been associated with risk for certain birth defects (Alwan and others, 2007; Polen 
and others, 2013); or coping behaviors, such as smoking, drinking, or illicit drug use. In the 
NBDPS interview, women were asked about the use of medications that could be used to 
treat depression. The interview questions, however, did not ask women about the reason for 
use; as a result, depression could not be distinguished from other possible indications for use 
(e.g., anxiety, post-traumatic stress disorder, or obsessive compulsive disorder). The BD-
STEPS interview includes questions designed to make this distinction, and to obtain 
information on symptoms and duration of the condition. Other chronic conditions about 
which detailed questions are asked in the BD-STEPS interview are: thyroid disease, 
autoimmune disease, migraines, cardiac arrhythmias and other heart conditions, anxiety, and 
attention deficit hyperactivity disorder ADHD.
Diabetes, obesity, physical activity, and bariatric surgery: Maternal pregestational 
diabetes and obesity are known risk factors for specific types of birth defects (Correa and 
others, 2008; Stothard and others, 2009) and the prevalence of both conditions are increasing 
in the United States (4; Flegal and others, 2012). Obesity and diabetes are distinct, but 
interrelated conditions. Few data are published on whether or not physical activity reduces 
the risk for birth defects attributable to diabetes or obesity (Flak and others, 2012). Although 
bariatric (weight loss) surgery is effective in improving certain health outcomes related to 
obesity, it is also associated with increased risk for certain pregnancy complications and 
adverse birth outcomes (Belogolovkin and others, 2012); furthermore, it is unknown 
whether it modifies the association between obesity and birth defects. BD-STEPS data will 
help us to explore the complexities of these health conditions and their associations with 
birth defects.
Medications: Medications are a common exposure during pregnancy, with approximately 
one-half of pregnant women reporting use of at least one prescription medication during the 
first trimester (Mitchell and others, 2011); even more women report use of over-the-counter 
medication during pregnancy (Werler and others, 2005). New medications are constantly 
being introduced to the market, but pregnant women are almost always excluded from 
clinical trials due to concerns about potential harm to the fetus. In addition to new 
medications, women are using existing medications for new indications, often at different 
dosages. For example, medications traditionally considered as antiepileptics are increasingly 
being used to treat migraines (Rogawski and Loscher, 2004) and to aid in weight loss 
(Garvey and others, 2012).
Although the NBDPS interview collected considerable information about medication use, 
the BD-STEPS interview will collect even more detailed data, including additional 
information on dose and indication for use and by expanding the list of chronic conditions 
for which medications are taken, with follow-up questions about medications used to treat 
those conditions.
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Genetics
In contrast to buccal (cheek) cell swabs collected in NBDPS, residual samples from 
newborn metabolic screening blood spots will be used to evaluate genetic susceptibility and 
biologic markers of exposure among live births in BD-STEPS. The collection of newborn 
metabolic screening blood spots is completed by collecting blood from infant heel sticks on 
filter paper soon after the infant’s birth.
Newborn blood spots have several advantages over buccal swabs: specimen collection is not 
required, reducing the burden on participants and potential errors/contamination during 
sample collection as well as reducing the cost. In addition, biomarkers present at the time of 
birth can be measured, allowing for evaluation of inflammatory cytokines (Keustermans and 
others, 2013), biochemical parameters (Paglia and others, 2010), DNA methylation (Wong 
and others, 2008), and environmental exposures such as heavy metals and persistent 
compounds (Chaudhuri and others, 2009). Disadvantages of this method are that samples are 
only available for liveborn infants in states that retain the newborn bloodspots and the lack 
of parental DNA samples.
For the Centers that require parental consent to obtain identified newborn blood spots, a 
written consent form requesting access to their infant’s residual newborn blood spots and a 
newborn blood spot question and answer sheet are included with the interview thank-you 
letter along with a $10 gift card. For parents of multiples (e.g. twins or triplets), the 
interview thank-you letter and the written consent forms will ask for access to residual blood 
spots from the case or control infant included in BD-STEPS and the index infant’s multiple 
sibling(s) who are not study participants.
Because individual defects are rare, many years of data collection are required to obtain 
enough samples to complete a valid etiologic study for a specific birth defect. Residual 
newborn blood spot specimens will be retained locally either by the Center or at the state 
health department. Each Center is responsible for processing and completing quality control 
analyses on the specimens before use. To ensure that each laboratory conducting genetic and 
epigenetic analyses of the newborn blood spot specimens is proficient in their respective 
laboratory techniques, an external quality assessment will be used for laboratories planning 
to conduct such research.
New components
Data linkages—We plan to link BD-STEPS data with selected existing environmental, 
surveillance, healthcare claims and clinical data to enhance the utility of the study data to 
explore important public health questions about birth defects. Such linkages can be used to 
validate self-reported data, evaluate associations of birth defects with additional exposures 
(e.g. environmental data), and conduct health services and outcomes research. For example, 
data from NBDPS have been successfully linked to environmental data on air pollution 
(Stingone and others, 2014) and water quality. For the water quality studies, NBDPS 
geocoded residence data were linked to water source maps for which water quality measures 
were available. Analyses to date have focused on nitrate exposure and selected birth defects 
(Brender and others, 2013), and work is currently underway to examine associations 
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between exposure to water disinfection byproducts and orofacial clefts, and other birth 
defects. Additionally, linkage to longitudinal datasets can provide a picture of the impact of 
birth defects across the lifespan as well as the changing met and unmet needs of those living 
with birth defects.
In addition, selected linkages between maternal responses in the BD-STEPS interview and 
other clinical data sources will allow validation of these self-reports by estimating bias and, 
if present, adjusting for bias, thus improving confidence in study findings. For examples, the 
Massachusetts Center led a project that linked NBDPS maternal reports of artificial 
reproductive therapy to clinical data from the Society for Assisted Reproductive 
Technologies (Liberman and others, 2014) and the Utah Center led a project that linked self-
reported NBDPS smoking data to data from other sources (Srisukhumbowornchai and 
others, 2012).
Online questionnaires—Online questionnaires are increasingly being used in studies of 
pregnancy and health outcomes (Boston University Slone Epidemiology Center; Huybrechts 
and others, 2010). BD-STEPS plans to implement the use of supplemental online 
questionnaires (paper questionnaires will be made available upon request). In the BD-
STEPS telephone interview, women are asked about their willingness to participate in future 
online questionnaires and to provide their email address. Those women willing to participate 
in this supplemental part of the study are eligible to receive periodic online surveys from 
BD-STEPS. The initial online questionnaire module, which will be released after the start of 
the study, will focus on occupational exposures. All women who reported working during 
early pregnancy in certain occupations and who indicated their willingness to participate in 
future online questionnaires will receive an email invitation to participate in the online 
survey and will be asked detailed questions about their potential exposures specific to that 
occupation. This first online questionnaire will serve as a pilot project to assess participation 
and the potential for selection bias, and associated costs. If this method yields useable 
information at an acceptable cost, online questionnaires on a variety of topics will be 
developed and periodically released throughout the course of the study.
NEED FOR BD-STEPS
Various approaches are used to improve our current understanding of the etiology and 
prevention of birth defects. Existing birth defects surveillance systems can be used to 
examine descriptive epidemiology on a population level and tend to have excellent 
diagnostic information, especially if based on active ascertainment. In some states, 
surveillance data can be linked to other data resources to explore more specific questions, 
such as the association of residential proximity to environmental exposures or 
neighborhood-level socioeconomic level with birth defects risks. Teratogen Information 
Services (TIS) typically collect information on pregnant women who contact TIS regarding 
concerns about various exposures, especially medications. Although not population-based, 
TIS data can address specific exposures of concern, especially newly emerging ones, and 
potentially generate important leads for etiologic analyses. Existing administrative databases 
(e.g., Healthcare Cost and Utilization Project data, proprietary health insurance claims 
databases, or Medicaid data) often contain detailed information about treatments and 
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outcomes within relatively large populations. Although the diagnostic specificity and 
accuracy of the birth defects diagnosis in administrative data sources may be problematic, 
linkage with population-based birth defects surveillance systems, which often use rigorous 
clinical diagnostic procedures, can minimize this limitation. However, the underlying 
population that these data sources represent may be ill-defined, and often are not 
representative of the general public. Thus additional approaches to studying etiology and 
prevention are needed.
BD-STEPS has several unique features that enhance its ability to contribute to our 
understanding of the causes of birth defects – with the ultimate goal of prevention. The 
study includes abstraction of detailed and standardized diagnostic data on specific birth 
defects, which is rarely available from existing administrative data sources. The methods of 
case and control selection are population-based. Exposure assessment is based on primary 
data collection (telephone interviews) rather than administrative datasets or aggregate 
information, which enables collection of detailed information on investigator-selected 
exposures, as opposed to secondary analysis of data available from existing systems that 
may not have been designed for etiologic research.
Each research approach has its own set of strengths and weaknesses. For retrospective case-
control studies such as BD-STEPS these include for instance selection bias and reliance on 
self-reported exposure data. In the end, the strength of epidemiological findings often rests 
on their coherence across different study populations and study designs.
CONCLUSIONS
The goal of BD-STEPS is to identify modifiable risk factors for selected structural birth 
defects. BD-STEPS aims to extend and expand beyond the strong foundation established by 
NBDPS. The longevity of the collaborative efforts of the CBDRP provides a unique 
opportunity to combine data across studies, a major strength of BD-STEPS that will allow 
for unprecedented statistical power for analyses of less common exposures. The design of 
BD-STEPS was based largely on the knowledge gained and lessons learned from NBDPS. 
Results from BD-STEPS will provide women, their partners, and healthcare providers with 
information they need to make decisions that will promote the healthiest pregnancies 
possible.
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Table 1
Description of catchment areas for the Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS) 
study sites
BD-STEPS study site Description of catchment area Approximate annual 
birth population of 
catchment area
Arkansas Entire state 37,000
California San Joaquin Valley counties (Fresno, Kern, Kings, Madera, Merced, San Joaquin, 
Stanislaus, and Tulare)
65,000
Georgia Metropolitan Atlanta counties (DeKalb, Fulton, and Gwinnett) 35,000
Iowa Entire state 40,000
Massachusetts Central and Eastern counties (Barnstable, Essex, Middlesex, Norfolk, Plymouth, Suffolk, 
and Worcester)
58,000
North Carolina Perinatal Care Regions II and IV counties (Alamance, Alexander, Allegheny, Ashe, 
Avery, Burke, Caldwell, Caswell, Catawba, Chatham, Davidson, Davie, Durham, 
Forsyth, Franklin, Granville, Guilford, Iredell, Johnston, Lee, Orange, Person, Randolph, 
Rockingham, Rowan, Stokes, Surry, Vance, Wake, Warren, Watauga, Wilkes, and 
Yadkin)
51,000
New York Selected Western and Downstate counties (Allegany, Bronx, Cattaraugus, Chautauqua, 
Erie, Genesee, Monroe, Niagara, Orange, Orleans, Putnam, Rockland, Westchester, and 
Wyoming)
66,000
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Table 2
Birth defects included in the Birth Defects Study to Evaluate Pregnancy exposures (BD-STEPS)
Defect category Estimated annual number of eligible cases across all study sites1
Spina bifida 135
Anophthalmia / microphthalmia 15
Anotia / microtia 20
Congenital heart defects
 Transposition of the great arteries (TGA) 80
 Tetralogy of Fallot 115
 Truncus arteriosus 20
 Pulmonary atresia 40
 Tricuspid atresia 20
 Coarctation of the aorta 130
 Hypoplastic left heart syndrome 40
 Anomalous pulmonary venous return 60
Cleft lip with or without cleft palate 230
Cleft palate 130
Esophageal atresia 60
Transverse limb deficiency 60
Diaphragmatic hernia 80
Gastroschisis 140
1
Based on 2005 – 2009 prevalence data from the Metropolitan Atlanta Congenital Defects Program
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Tinker et al. Page 15
Table 3
Topic areas included in the Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS) computer-
assisted telephone interview
Pregnancy history
Multiple gestation
Family history
Fertility treatments
Maternal health conditions
 Diabetes
 Cancer
 Heart problems
 Obesity
 Thyroid disease
 Asthma
 Epilepsy
 Migraine
 Autoimmune disease
 Transplant receipt
 Depression/anxiety
 Attention deficit hyperactivity disorder
 Genitourinary infections
 Fever
Medications
Herbals
Vitamins
Stress
Physical activity
Dental procedures
Smoking
Alcohol use
Residential history
Maternal occupation
Race/acculturation
Education
Insurance status
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